media – Page 9 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The United States may impose tariffs on drug imports. Many pharmaceutical companies responded with “close attention”

According to CCTV News, on April 8, there was news that the United States would impose tariffs on drugs. It is understood that the broad tariffs on US imports announced last week did not involve drugs, but at that time, it was reported that drugs would face separate tariffs. Pharmaceutical companies such as Hanyu Pharmaceutical, Kelun Pharmaceutical, and Tonghua Dongbao responded. Hanyu Pharmaceutical responded on April 9: “The company’s current products sold to the United States are mainly liraglutide and some raw materials. We and our partners are closely following the relevant developments. The relevant response needs to be studied after the specific situation of the US drug tariffs is clarified. The company has also been planning to expand into the European or Southeast Asian markets to reduce its dependence on the US market.” Kelun Pharmaceutical’s Securities Department responded: “We have just seen this news. The company’s relevant departments are ...
- Source: drugdu
- 83
- April 11, 2025
The United States will impose tariffs on drugs

On April 8, local time, US President Trump gave a speech saying that the United States will impose tariffs on drugs. Trump said that the United States does not produce its own drugs and other products that improve health. The price the United States pays for drugs is often many times higher than that of countries that produce drugs. Trump believes that once tariffs are imposed on drugs, pharmaceutical companies will open factories in the United States because the United States is the “largest market.” Last week, Trump announced a wide range of tariffs on US imports that did not involve drugs, but he said that drugs would face separate taxes. European pharmaceutical companies have warned in a meeting with the President of the European Commission on the 8th that US tariffs will accelerate the trend of the industry shifting from Europe to the United States. The pharmaceutical industry trade ...
- Source: drugdu
- 77
- April 11, 2025
Zhifei Biotech’s bivalent dysentery vaccine is ready to start enrolling subjects

On April 8, Zhifei Biotech (300122) issued an announcement that it was recently learned that the bivalent dysentery conjugate vaccine developed by the company’s wholly-owned subsidiary Zhifei Green Bamboo has obtained the Phase III clinical trial approval from the Bangladesh Drug Administration and is ready to start enrolling subjects. The vaccine is designed to prevent bacterial dysentery caused by Shigella flexneri and Shigella sonnei, which affects 164.7 million people worldwide each year, especially in developing countries and children under 5 years old. In the first three quarters of 2024, Zhifei Biotech achieved revenue of 22.786 billion yuan and net profit attributable to the parent of 2.151 billion yuan. https://finance.eastmoney.com/a/202504083369655980.html
- Source: drugdu
- 79
- April 11, 2025
The oral vaccine developed by Kangtai Biological and its subsidiaries has started Phase III clinical trials

On April 9, Kangtai Biological (300601) issued an announcement, announcing that the oral pentavalent reassortant rotavirus attenuated live vaccine (Vero cells) developed by it and its wholly-owned subsidiary Minhai Biological has completed the preparations for Phase III clinical trials and successfully completed the first subject enrollment. This marks that the product development has made phased progress and further promoted the company’s vaccine development process. This Phase III clinical trial adopts a multi-center, randomized, double-blind, placebo-controlled design to evaluate the protective efficacy, safety and immunogenicity of the vaccine in Chinese infants and young children. https://finance.eastmoney.com/a/202504093371486634.html
- Source: drugdu
- 81
- April 11, 2025
【EXPERT Q&A】Has stem cell therapy entered the clinical stage?

Drugdu.com expert’s response: Stem cell therapy has entered the clinical treatment stage and is continuously advancing globally, with multiple countries approving related therapies for specific diseases, while numerous clinical trials are underway to verify their safety and efficacy. I. Approved Stem Cell Therapies United States: In 2010, the FDA approved Prochymal® (allogeneic bone marrow mesenchymal stem cells) for the treatment of pediatric graft-versus-host disease (GvHD), marking the world’s first approved stem cell drug. European Union: In 2015, the EU approved Holoclar® (autologous limbal stem cells) for the treatment of severe limbal stem cell deficiency. Japan: In 2018, Japan approved Temcell® (allogeneic bone marrow mesenchymal stem cells) for the treatment of GvHD. South Korea: In 2022, South Korea approved Cartistem® (umbilical cord blood-derived mesenchymal stem cells) for the treatment of degenerative arthritis. China: In 2024, China’s National Medical Products Administration (NMPA) approved “Aimaituosai Injection” (human umbilical cord mesenchymal stem cell injection) ...
- Source: drugdu
- 91
- April 11, 2025
PHARMCHINA

Organiser: Reed Sinopharm Exhibitions Time: May 21–23, 2025 Address: No. 380, Yuejiang Middle Road, Haizhu District, Guangzhou City Exhibition hall: Canton Fair Complex – Pazhou Hall, Guangzhou Product range: Chemical Pharmaceuticals Proprietary Chinese Medicines (Ethnic Medicines) OTC Drugs Medical Consumables Medical Devices Biotechnology & Innovation (Genetic Testing, Diagnostic Reagents, Pharmaceutical R&D, Contract Customization, Biopharmaceuticals, Biotechnology, Biological Products, etc.) Chinese Herbal Materials/Decoction Pieces (Bulk Decoctions, Traditional Decoctions, Refined Packaged Decoctions, Small-Package Decoctions, Orally Administered Solid Decoctions, Crushed-Wall Decoctions, Chinese Medicine Formula Granules, Novel Decoction Forms, Chinese Herbal Materials, Production Equipment for Decoction Pieces, Packaging for Decoction Pieces, etc.) Moxibustion & Moxa Products Traditional Chinese Medicine (TCM) Wellness (TCM Wellness Centers, Foot Bath/Spa/Herbal Bath Products, TCM Cosmetics, Chinese-Style Medicinal Oils/Balms, Medicinal Diets, Health Tonics, etc.) TCM Diagnostics & Equipment (TCM Diagnostic Devices, TCM Instruments, Traditional Chinese Medicine Processing Equipment, etc.) Internet + Pharmaceuticals (B2B, B2C, O2O E-commerce Platforms, Health Management Platforms, Smart Medicine Cabinets, ...
- Source: drugdu
- 102
- April 10, 2025
【EXPERT Q&A】Are generic drugs really worse than the original?

Drugdu.com expert’s response: Are generic drugs necessarily inferior to brand-name (originator) drugs? The specific differences depend on the quality level of the generic drugs. I. Core Differences Between Generic and Brand-Name Drugs 1. Research Foundation and Validation Brand-Name Drugs: Require foundational research, preclinical studies, multi-phase clinical trials (Phases I–III), and post-marketing surveillance (Phase IV) to verify safety, efficacy, and long-term impacts. Generic Drugs: Demonstrate bioequivalence to brand-name drugs in terms of absorption rate and extent through bioequivalence trials, without replicating the original clinical trials. 2. Quality Standards and Consistency Brand-Name Drugs: Utilize proprietary manufacturing processes and quality control systems, often involving patented technologies. Generic Drugs: Must pass consistency evaluations to ensure equivalence in active ingredients, dosage forms, and routes of administration to brand-name drugs, though excipients and manufacturing processes may differ. II. Quality Variations in Generic Drugs 1. High-Quality Generic Drugs Some generic drugs achieve efficacy and safety comparable to ...
- Source: drugdu
- 93
- April 9, 2025
Career Development Guide for API and Pharmaceutical Intermediate Sales Professionals

In the global pharmaceutical supply chain, sales professionals specializing in Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates play a crucial role. To excel in this competitive and dynamic international market, continuous enhancement of skills and knowledge is essential. Here are some key strategies to advance your career in pharmaceutical foreign trade sales: 1. Deepen Product and Industry Knowledge A thorough understanding of the chemical properties, production processes, quality standards, and applications of the APIs and intermediates you sell is fundamental to building trust with clients. Staying informed about global pharmaceutical regulations, market trends, and policy changes enables you to make informed decisions in the international marketplace. For instance, being familiar with the “Guidelines for the Development of the Pharmaceutical Industry” can provide insights into industry directions. 2. Enhance Cross-Cultural Communication and Negotiation Skills Engaging with clients from diverse cultural backgrounds is a daily aspect of international sales. Understanding and respecting ...
- Source: drugdu
- 83
- April 8, 2025
Zhongke Chuangxing Angel+Exclusive Investment Round in ‘Saiyun Biology’

Recently, Saiyun Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as “Saiyun Biotechnology”), a biotechnology company specializing in the development of international cutting-edge delivery carrier technology and innovative drug therapies, announced the completion of tens of millions of angel+round financing. This round of financing is exclusively invested by Zhongke Chuangxing, and the funds raised will mainly be used to accelerate the development process of the company’s self-developed pipelines. Saiyun Biotechnology is an enterprise dedicated to the research and development of targeted delivery technology and innovative drug therapies. It has successfully developed a biomimetic delivery system with independent intellectual property rights, which is different from mainstream delivery carrier systems. After rational transformation, the system can achieve precise cell delivery of various types of payloads, and has significant advantages in specificity recognition, payload compatibility, protection, and production cost. As an emerging type of delivery system, the research and development progress of “Saiyun Biology” ...
- Source: drugdu
- 104
- April 8, 2025
Hengrui, Baiji, and China Biopharmaceuticals are leading the way, and China’s innovative drugs have entered the era of “billions”

In the wave of global pharmaceutical innovation, China’s innovative pharmaceutical industry is emerging and making great strides forward. From the recent financial reports released by major pharmaceutical companies, it can be seen that in 2024, Hengrui Pharmaceutical, BeiGene, and China Biopharmaceutical will become the leading forces in promoting China’s innovative drugs towards the era of “billions” with outstanding innovation strength and market performance, reflecting the vigorous and upward development trend of China’s innovative drugs. 1. Hengrui Innovative drug revenue exceeds 13.8 billion yuan, accounting for more than half of total sales revenue Hengrui, as the leader in innovative drugs in China, has achieved great success in 2024. According to its annual report released on March 30th, Hengrui achieved a total operating revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit attributable to shareholders of the listed company of 6.337 billion yuan, a significant year-on-year ...
- Source: drugdu
- 119
- April 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.